Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and {REMOVEPT} price target on aTyr Pharma (NASDAQ: ATYR).

The analyst commented, “We Are Hosting aTyr Management for a Virtual Fireside Chat. aTyr has a big P3 binary in 3Q25 for efzofitimod in pulmonary sarcoidosis. We will go through the key investor debates around this readout in detail. We will touch on the expectations for the interim P2 readout in 2Q25 for efzofitimod in SSc-ILD.”

For an analyst ratings summary and ratings history on aTyr Pharma click here. For more ratings news on aTyr Pharma click here.

Shares of aTyr Pharma closed at $3.10 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Boeing lands two U.S. defense contracts worth over $711M